Concurrent cor triatriatum sinister and levoatriocardinal vein in an 11-year-old boy presenting with foudroyant pulmonary edema after appendectomy: A living tribute to the mal-incorporation theory

Meng-Luen Lee*,1, Chiung-Fang Tu**
*Division of Pediatric Cardiology, **Department of Pediatrics, Changhua Christian Children’s Hospital; Changhua-Taiwan
1Department of Pediatrics, School of Medicine, Kaohsiung Medical University; Kaohsiung-Taiwan

Introduction

Cor triatriatum sinister (CTS) is a rare cardiovascular malformation, in which the left atrium (LA) is separated by a membrane into the proximal and distal LA chambers (1). Levoatriocardinal vein (LACV) is an even rarer vascular anomaly that connects the LA (or tributaries of pulmonary vein) with the left innominate vein (an embryologic derivative from the cardinal system) (2). Development of the pulmonary vein and systemic venous sinus are spatiotemporally correlated during embryogenesis (3). Here, we report a case of an 11-year-old boy unexpectedly presenting with acute pulmonary edema after appendectomy. Echocardiography and chest computed tomography (CT) revealed a combination of CTS and LACV, which were then surgically corrected. We briefly reviewed the English literature reporting the pediatric patients with concurrent CTS and LACV, compared their clinical profiles with ours, highlighted the pathomechanism of a delay onset of clinical manifestations in our patient, and provided an anatomical feature indicating the mal-incorporation theory for the embryogenesis of CTS.

Case Report

An 11-year-old boy was transferred to our hospital due to overt tachycardia and tachypnea two days after appendectomy, and admitted to the pediatric intensive care unit under the impression of acute cardiopulmonary failure. At the time of admission, his height was 135 cm, weight 61 kg, heart rate 126 bpm, respiratory rate 44 bpm, and blood pressure 141/83 mm Hg. Chest auscultation revealed moist rales. There was a grade II/VI systolic ejection murmur over the left upper sternal border. Preoperative chest radiogram showed only scoliosis (Fig. 1a). However, pulmonary edema was noted two days after appendectomy (Fig. 1b). The N-terminal pro-brain natriuretic peptide concentration was 2593 pg/mL (>450 pg/mL) and troponin-I concentration 0.09 ng/mL (>0.03 ng/mL). Two-dimensional echocardiography with color Doppler revealed a secundum atrial septal defect (ASD II), a limiting membrane in the LA indicating CTS (Fig. 1c), a 7.5-mm orifice in this membrane, and a pressure gradient of 10.8 mm Hg across the orifice (Fig. 1d). Pulmonary acceleration time was 80 ms, and pulmonary artery pressure 40 mm Hg. Chest CT showed a Lam type A1 CTS (Fig. 1e, 1f, and 1g) and a large LACV (Fig. 1h). After obtaining an informed consent, cardiovascular surgery was performed, including excision and removal of the limiting membrane within the LA, repair of the ASD II, and ligation of LACV. Follow-up chest radiogram and echocardiography showed regression of pulmonary edema and pulmonary hypertension, respectively. Meanwhile, normalization of N-terminal pro-brain natriuretic peptide and troponin-I were also achieved. The patient was discharged uneventfully.

Discussion

The most noteworthy point in the present case report is that there was a deep groove noted from the external aspect of the

<table>
<thead>
<tr>
<th>No/Age/Sex</th>
<th>Obstruction</th>
<th>Association</th>
<th>IAS</th>
<th>LACV</th>
<th>Outcome</th>
<th>Author (Reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/3 wk/F</td>
<td>CTS, CoA</td>
<td>CoA</td>
<td>ASD II</td>
<td>LA</td>
<td>INV</td>
<td>Expired</td>
</tr>
<tr>
<td>2/4 wk/M</td>
<td>CTS</td>
<td>-</td>
<td>PFO</td>
<td>LA</td>
<td>RSVC</td>
<td>Survived</td>
</tr>
<tr>
<td>3/10 wk/F</td>
<td>CTS</td>
<td>-</td>
<td>PFO</td>
<td>LUPV</td>
<td>INV</td>
<td>Survived</td>
</tr>
<tr>
<td>4/3 mo/F</td>
<td>CTS</td>
<td>-</td>
<td>PFO</td>
<td>LA</td>
<td>RSVC</td>
<td>Survived</td>
</tr>
<tr>
<td>5/4 mo/F</td>
<td>CTS</td>
<td>-</td>
<td>Intact</td>
<td>LA</td>
<td>RSVC</td>
<td>Survived</td>
</tr>
<tr>
<td>6/3 mo/F</td>
<td>CTS</td>
<td>-</td>
<td>Intact</td>
<td>LA</td>
<td>RSVC</td>
<td>Survived</td>
</tr>
<tr>
<td>7/11 yr/M</td>
<td>CTS</td>
<td>-</td>
<td>ASD II</td>
<td>LUPV</td>
<td>INV</td>
<td>Survived</td>
</tr>
</tbody>
</table>

ASD II - secundum atrial septal defect; CoA - coarctation of the aortic arch; CTS - cor triatriatum sinister; F – female; IAS - interatrial septum; INV - innominate vein; LA - left atrium; LACV - levoatriocardinal vein; LUPV - left upper pulmonary vein; M – male; mo – month; PFO - patent foramen ovale; RSVC - right superior vena cava; VSD - ventricular septal defect; wk – week; yr - year
chest CT. This external deep groove anatomically corresponds to the internal location of the limiting membrane that is downstream the proximal LA chamber. This is a living tribute to the embryogenesis of the mal-incorporation theory indicating that CTS occurs due to a failure of incorporation of the common pulmonary vein into the primitive LA during the fifth embryonic week (1). Albeit development of the pulmonary veins and systemic venous sinus are spatiotemporally correlated during embryogenesis (3), a combination of CTS and LACV is extremely rare (2). Till date, there are only six reported cases of pediatric patients with concomitant CTS and LACV in the English literature (2, 4, 5). The clinical and anatomical features of the seven pediatric patients, including our case, with concomitant CTS and LACV are tabulated in Table 1. Our patient, aged 11 years, was much older than the other six patients, who were aged from 3 weeks to 4 months. The clinical manifestations of our patient could be confounded by scoliosis, obesity, inadequate physical activity, low socioeconomic status, and reluctance to call for medical assistance, which may render a delayed diagnosis of CTS and/or LACV. In addition, three anatomical features were functionally contributive to decompress the LA, including a moderate-size ASD II (9.1 mm) above the membrane, a not-so-small orifice in the membrane (7.5 mm), and a large LACV (20.0 mm). Hemodynamically, there was a left-to-right shunt in our patient, which mimicked a shunt of a non-restrictive or large ASD II. Provided the pulmonary venous inflow is not significantly impeded, patients with concurrent CTS and LACV could be clinically asymptomatic. We highlight that obstructive left heart disease(s) should be scrutinized by echocardiography and/or chest CT in pediatric patients unexpectedly presenting with postoperative pulmonary edema or pulmonary hypertension.

**Conclusion**

Given that development of the pulmonary veins and systemic venous sinus are spatiotemporally correlated, a combination of CTS and LACV, though rare, is not impossible. Echocardiography and chest CT are useful examinations to unmask the Janus face of CTS and LACV in patients presenting with pulmonary edema and pulmonary hypertension.

**Informed consent:** Written informed consent was obtained from the parents of the patient for the publication of the case report and the accompanying images.

**References**

1. Van Praagh R, Corsini I. Cor triatriatum: pathologic anatomy and a consideration of morphogenesis based on 13 postmortem cases and a study of normal development of the pulmonary vein and atrial septum in 83 human embryos. Am Heart J 1969; 78: 379-405. [CrossRef]


Address for Correspondence: Meng-Luen Lee, MD, Division of Pediatric Cardiology, Department of Pediatrics, Changhua Christian’s Children Hospital; No. 135 Nanhsiao St., 50050 Changhua-Taiwan
Phone: 886-4-7236595, Ext: 1902
E-mail: ferdielee@yahoo.com
©Copyright 2019 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2018.60980

Apixaban successfully resolved a warfarin-resistant left atrial appendage thrombus in a patient with end-stage renal disease on hemodialysis

Introduction

The left atrial appendage (LAA) is the major source of thromboembolism in patients with atrial fibrillation (AF). Warfarin or new oral anticoagulants (NOACs) have been used to treat the LAA thrombus; however, the use of NOACs is limited in patients with renal dysfunction. Here, we report the case of a patient with paroxysmal AF and end-stage renal disease (ESRD) requiring hemodialysis, in whom apixaban successfully and safely resolved a LAA thrombus refractory to warfarin.

Case Report

A 62-year-old female with a history of ESRD and on hemodialysis was referred to our electrophysiology department due to paroxysmal AF. Anticoagulation therapy with warfarin was started because her CHADS2-VASc score was 4 (hypertension, diabetes, congestive heart failure, and female gender), as well as amiodarone therapy for rhythm control. Transthoracic echocardiography demonstrated enlarged left atrium (LA) with a reduced left ventricular ejection fraction (25%). The coronary angiogram demonstrated no significant stenosis at the epicardial coronary artery. Transesophageal echocardiography (TEE) revealed a thrombus in the LAA (Video 1 & Fig. 1a). We targeted an INR of 2.0–2.5 with a monthly check up; however, labile INR was documented with time in a therapeutic range (TTR) of 45.8%. With maintaining warfarin and amiodarone, the patient experienced syncope. Tachycardia–bradycardia syndrome was documented, and therefore, a catheter ablation was planned. However, after approximately 2 years of warfarin anticoagulation therapy, TEE detected remaining thrombus (Fig. 1b). Therefore, warfarin was switched to a direct factor Xa inhibitor, apixaban at 5 mg bid. Patient’s PT and INR values were 19.4 and 1.78, respectively, at the time of replacement. Apixaban was initially prescribed at 2.5 mg bid as opposed to 5 mg bid recommended by the package labeling for fear of bleeding complications, and it was increased to 5 mg bid a month later. After 4 months of apixaban treatment, TEE revealed complete resolution of the LAA thrombus (Video 2 & Fig. 1c). Finally, catheter ablation was performed without complications, and the patient has since been in the sinus rhythm under continued anticoagulant treatment with apixaban. No thromboembolic or bleeding event occurred during the 26 months of the follow-up after the catheter ablation.

Discussion

Randomized controlled trials evaluating warfarin and NOACs have generally excluded patients with ESRD undergoing hemodialysis. Based on current guidelines, warfarin remains the anticoagulant of choice in these patients. However, a low TTR is the problem most likely intrinsic to hemodialysis patients due to multiple factors, which include drug interactions, high comorbidity burden, frequent interventions requiring interruption of anticoagulation, and subclinical vitamin K deficiency (1).

In a previous evaluation of the pharmacokinetics, pharmacodynamics, and safety of apixaban in eight patients with ESRD undergoing hemodialysis, it was demonstrated that the area under the curve (AUC) of apixaban was 36% higher for the ESRD patients than for those with normal renal function. The AUC decreased by 14% when apixaban was administered prior to hemodialysis. However, the calculated hemodialysis extraction ratio was negligible, with only 0.33 mg of the dose being removed (2). In another study, the AUC of apixaban was found to be increased by 44% in seven individuals with severe renal impairment (creatinine clearance ≤15 mL/min); however, the apixaban exposure (C max) was not affected by the presence of renal impairment (3). This information led to a labeling change approved by the FDA in 2014 to an apixaban dose of 5 mg bid in hemodialysis patients without dose adjustment necessary for renal impairment alone. In a recent retrospective study, the bleeding rates were similar in ESRD patients undergoing hemodialysis who were either on apixaban or on warfarin for the treatment or prevention of venous thromboembolism (4).

Apixaban has the least renal excretion among four NOACs and is allowed to be used in patients requiring dialysis. Therefore, we